Intervention not reported
Anthropometric outcomes: number of children with WHZ in moderate wasting range on discharge Defined as WHZ between −3 and −2 (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with WHZ in moderate… (moderate certainty).
1 finding from 1 review
Moderate‐severe neurodevelopmental impairment at 18 to 26 months ‐ not measured · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Developmental delay –motor (mild, moderate or severe) · women at risk of preterm birth
Dexamethasone showed no clear difference in developmental delay –motor (mild, moderate or severe) compared with betamethasone – child outcomes (moderate certainty).
1 finding from 1 review
Intellectual impairment: developmental delay – cognitive or language (mild, moderate or severe) · women at risk of preterm birth
Dexamethasone showed no clear difference in intellectual impairment: developmental delay – cognitive or language… compared with betamethasone – child outcomes (moderate certainty).
1 finding from 1 review
Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants with hypoglycaemia
Oral dextrose gel showed no clear difference in major neurological disability at age 2 years or olderb Defined as… compared with control (low certainty).
1 finding from 1 review
Is moderately stunted · children (0 to 17 years) and adults (≥ 18 years) or households
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Is moderately stunted · children (0 to 17 years) and adults (≥ 18 years) or households
It is very uncertain whether summary of findings: unconditional cash transfer changes is moderately stunted compared with no unconditional cash transfer: primary outcomes (very low certainty).
1 finding from 1 review
RR 1.02 [0.91, 1.14]
3298 participants
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.9
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.9
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus no treatment ‐ mild to moderate discomfort or pain related to treatment ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with no treatment (very low certainty).
1 finding from 1 review
OR 8.62
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC plus 5‐FU ‐ mild to moderate pain related to treatment ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.9
Studies not reported
Very low
Intervention not reported
Moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 5452(6 RCTs)
The intervention showed no clear difference in moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3184(3 RCTs)
The intervention probably leads to lower moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2037(2 RCTs)
The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2651(2 RCTs)
The intervention showed no clear difference in moderate to severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (low certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 4989(4 RCTs)
The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD TRIPLE vs MD TRIPLE№ of participants: 3470(3 RCTs)
The intervention showed no clear difference in moderate to severe exacerbations ‐ HD TRIPLE vs MD TRIPLE№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ TRIPLE vs DUAL№ of participants: 8173(5 RCTs)
The intervention leads to lower moderate to severe exacerbations ‐ TRIPLE vs DUAL№ of participants:… (high certainty).
1 finding from 1 review
Death or moderate disability (mRS > 3) at 6 to 12 months · malignant cerebral oedema after ischaemic stroke
Summary of findings table ‐ surgical decompression probably leads to lower death or moderate disability (mRS > 3) at 6 to 12 months compared with medical treatment alone (moderate certainty).
1 finding from 1 review